Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $76.50 | Total: $382.50 |
| 1 | 10 | $64.80 | Total: $648.00 |
| 1 | 25 | $54.90 | Total: $1,372.50 |
| 1 | 50 | $46.80 | Total: $2,340.00 |
| 1 | 100 | $40.50 | Total: $4,050.00 |
Overview
Tovinontrine (IMR-687) (IMR-687) is a potent and selective inhibitor of phosphodiesterase-9 (PDE9), designed to target sickle cell disease treatment. It exhibits high efficacy, with IC 50 values of 8.19 nM and 9.99 nM for PDE9A1 and PDE9A2, respectively [1].
Chemical Properties
| Molecular Formula | C21H26N6O2 |
| Molecular Weight | 394.47 |
| CAS Numbers | 2062661-53-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(ncc2c(=O)[nH]1)C1CCOCC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
McArthur JG, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020;105[3] 623-631.